Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04950127 · ClinicalTrials.gov registry record · Phase 3
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 238
- Enrollment target
NCT04950127 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 238 participants.
The verdict
NCT04950127, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 238 participants
- Enrollment target
Study Summary
This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
Interventions
- DRUG Placebo
- DRUG Linerixibat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2024-12-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04950127
The ClinicalTrials.gov registry entry for NCT04950127 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04950127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04950127 about?
NCT04950127 is a clinical study titled "Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)". This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
What is the current status of trial NCT04950127?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 238 participants. The study started on 2021-08-27. Estimated completion is 2024-12-20.
What interventions are being tested in trial NCT04950127?
The interventions under investigation include: Placebo (DRUG), Linerixibat (DRUG).
Who is sponsoring clinical trial NCT04950127?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.